Table 3.
Prognostic factor |
Category |
n |
Median (months) |
Univariate |
Multivariate |
||||
---|---|---|---|---|---|---|---|---|---|
Hazard ratio | 95% CI | p value* | Hazard ratio | 95% CI | p value** | ||||
Age (years) |
≦ 70 |
43 |
17.0 |
1.00 |
0.35 - 1.03 |
0.062 |
|
|
|
>70 |
35 |
22.7 |
0.60 |
|
|
|
|||
PSA at DTX initiation (ng/ml) |
≦ 20 |
39 |
39.6 |
1.00 |
1.94 - 6.11 |
<0.001 |
1.00 |
|
0.058 |
>20 |
39 |
12.6 |
3.44 |
2.07 |
0.98 - 4.37 |
|
|||
PSADT (months) |
>2.4 |
38 |
31.4 |
1.00 |
1.48 - 4.41 |
0.001 |
1.00 |
|
0.033 |
≦ 2.4 |
40 |
16.7 |
2.56 |
1.88 |
1.05 - 3.36 |
|
|||
ECOG performance status |
≦ 1 |
68 |
20.3 |
1.00 |
1.55 - 6.26 |
0.001 |
1.00 |
|
0.740 |
2 |
10 |
4.1 |
3.11 |
1.16 |
0.49 - 2.74 |
|
|||
Gleason score |
≦ 7 |
21 |
31.2 |
1.00 |
0.89 - 3.00 |
0.113 |
|
|
|
>8 |
57 |
18.2 |
1.63 |
|
|
|
|||
Armstrong risk classification |
Good |
51 |
30.1 |
1.00 |
|
|
1.00 |
|
0.060 |
Intermediate |
17 |
14.2 |
2.48 |
1.32 - 4.66 |
<0.001 |
1.33 |
0.60 - 2.97 |
0.487 |
|
Poor | 10 | 5.7 | 6.58 | 3.07 - 14.11 | 3.21 | 1.17 - 8.80 | 0.024 |
Abbreviations: CI, confidence interval; PSA, prostate-specific antigen; PSADT, prostate-specific antigen doubling time; ECOG, Eastern Cooperative Oncology Group; ALP, alkaline phosphatase. *log rank test. **Cox proportional hazards model.